Novartis announced on August 25 that the China Drug Administration has approved a combination of radioligand therapy drug Pavital® and an androgen receptor pathway inhibitor to treat prostate-specific membrane antigen-positive metastatic hormone-sensitive prostate cancer.

Zhitongcaijing · 3d ago
Novartis announced on August 25 that the China Drug Administration has approved a combination of radioligand therapy drug Pavital® and an androgen receptor pathway inhibitor to treat prostate-specific membrane antigen-positive metastatic hormone-sensitive prostate cancer.